Abstract Tendon pathology is a general term used to describe a group of musculoskeletal conditions related to tendons and surrounding structures. There is only limited evidence available regarding the exact aetiology and natural history of tendon pathology. In hypercholesterolaemia environments, lipids could accumulate within the extracellular matrix of the tendon and thus affect the mechanical properties of the tendon. Current evidence suggested that hypercholesterolaemia was an important risk factor in the development and progression of tendon pathology. The severity of hypercholesterolaemia was correlated with the severity of tendon pathology.
Background
Tendon pathology is a general term used to describe a group of musculoskeletal conditions related to tendons and surrounding structures [1] . Tendon pathology could be broadly classified into traumatic, degenerative and overuse-related tendinopathy. Rotator cuff tears, Achilles tendinopathy, Achilles tendon rupture, and tennis elbow are common examples of these conditions. Tendon xanthoma is a special type of tendon pathology. There is only limited evidence available regarding the exact aetiology and natural history of tendon pathology [2] . Possible etiologic factors may include aging, overuse, trauma, biomechanical abnormalities, glucocorticoids use, quinolone antibiotics use, microcirculation, and metabolic disorders [3] . Because the pathogenesis of tendon pathology is so complex and involves a variety of biological phenomena, there is no consistently effective treatment available for tendon pathology. Clinically available treatment options may include nonsteroid antiinflammatory drug, corticosteroid injection, platelet-rich plasma injection, low-energy laser stimulation, extracorporeal shock wave therapy, and surgical interventions [3] . Although these approaches may relieve the symptoms in the short term, there is presently limited scientific evidence supporting these therapies and their efficacy.
Hypercholesterolaemia is a systemic metabolic disease characterised by abnormally high levels of cholesterol in the blood. Hypercholesterolaemia is defined as elevated amounts of total cholesterol (240 mg/dL) in the blood. Hypercholesterolaemia has well-known impact on vascular systems and internal organs [4] . Recently, the influence of hypercholesterolaemia on musculoskeletal system has attracted much attention. In hypercholesterolaemia environments, lipids could accumulate within the extracellular matrix of the tendon and thus affect the mechanical properties of the tendon [5, 6] . Several studies have explored the relationship between hypercholesterolaemia and tendon pathology. Animal studies indicated that high levels of cholesterol would lead to poorer mechanical properties and adversely affect tendon healing after surgical repair [7e9], while clinical studies showed inconsistent results on the association between hypercholesterolaemia and tendon pathology [10, 11] . Better understanding of the relationship between hypercholesterolaemia and tendon pathology, the impact of hypercholesterolaemia on tendon structure and healing as well as the mechanisms of hypercholesterolaemia in the development and progression of tendon pathology would aid the development of an effective treatment strategy.
The purpose of this review was (1) to summarise the association between hypercholesterolaemia and tendon pathology, (2) to discuss the pathogenic mechanisms in causing and exacerbating tendon pathology and (3) to explore the potential treatment strategies for tendon pathology in hypercholesterolaemia patients.
Epidemiology of tendon pathology in hypercholesterolaemia patients
The association between hypercholesterolaemia and tendon pathology was reviewed by searching the original research articles in PubMed. The search algorithm was "(tendon or tendinopathy) AND (hyperlipidaemia or dyslipidaemia or hypercholesterolaemia or statin)". There was significant heterogeneity among the included studies on study design, participants, grouping, sample size and statistical methods. Hypercholesterolaemia is defined as elevated amounts of total cholesterol (240 mg/dL) in the blood. The causes of hypercholesterolaemia include diet, lifestyle and genetics [12] . Based on the family history and genetics, hypercholesterolaemia could be divided into familial hypercholesterolaemia (FH) and nonfamilial hypercholesterolaemia (non-FH) [12] . The epidemiology of tendon pathology at FH and non-FH patients was summarised below.
Hypercholesterolaemia and tendon pathology in patients with FH
FH is an inherited genetic disorder, characterised by obviously elevated levels of low-density lipoprotein (LDL) cholesterol, xanthomas and family history of premature atherosclerosis. Based on the family history, FH could be classified as homozygous and heterozygous. The homozygous FH has a prevalence of one per million [13] , whereas heterozygous FH affects about one in 200e600 people [14] . Tendon xanthomas are cholesterol deposits within certain tendons, commonly on the Achilles tendons and extensor tendons of the hands [15] . Tendon xanthomas usually appeared in homozygous FH since childhood, while it started to develop after the age of 20 years in patients with heterozygous FH [16] . Approximately 20%e80% of FH patients with genetic diagnosis have tendon xanthomas [17] . It is unknown why some FH patients develop tendon xanthomas and others do not, even with the similar genetic factors. Furthermore, FH could present as Achilles tendinopathy before the development of tendon xanthomas [18] . Measurement of serum cholesterol in patients presenting with painful Achilles tendon could lead to early diagnosis of FH.
Hypercholesterolaemia and tendon pathology in patients without FH
Overuse is considered a major causative factor for tendinopathy. However, a large portion of cases occurred among completely nonactive individuals [19] . People with high body mass index are more likely to suffer from tendinopathy [20] . Though overweight directly affects tendon loading, it is unlikely that increased tendon loading adequately explains these relationships [21] . Alternate mechanisms linking obesity and tendinopathy may be high prevalence of metabolic disorders in the obesity.
Hypercholesterolaemia has been implicated as a risk factor for tendon pathology, but the evidence is mixed. Currently, 15 clinical studies explored the relationship between hyperlipidaemia and tendon pathology. Ten of 15 studies demonstrated that there was an association between dyslipidaemia and tendon pathology (Summarised in Table 1 ). Gaida et al [22] compared the serum lipid profile between participants with Achilles tendinopathy and those without Achilles tendinopathy and indicated that Achilles tendinopathy was associated with dyslipidaemia and the metabolic syndrome. Abboud et al [23] prospectively collected serum cholesterol and lipid profiles in patients with or without rotator cuff tears and indicated that patients with rotator cuff tears were more likely to have Patients with dyslipidaemia had significantly higher odds ratio of rotator cuff tears.
Yes hypercholesterolaemia. Lin et al [10] explored the effect of hyperlipidaemia on the development of rotator cuff disease and demonstrated that hyperlipidaemia was an independent risk factor for rotator cuff disease development. In contrast with these studies, Davis et al [24] compared the serum and synovial fluid lipid profile between participants with intact rotator cuff and rotator cuff tear requiring a repair. The authors indicated that there were no significant differences in any lipid values between patients with and without cuff tears. For FH patients, hypercholesterolaemia is associated with xanthoma formation. While for non-FH patients, there is a potential role of hypercholesterolaemia in predisposing to tendon pathology in the general population. It looks like 
Pathogenic mechanisms
Extracellular matrix remodelling and inflammation are reported to be two key factors in the development of atherosclerosis in hypercholesterolaemia patients [25] . There is limited evidence regarding the potential pathogenic mechanisms of hypercholesterolaemia on tendon. It is necessary to summarise the current evidence of the mechanisms of lipid deposition in tendon. Furthermore, the pathogenic mechanisms of hypercholesterolaemia on tendon were summarised from the following three points: inflammation, tendon structural changes and changes in mechanical properties ( Figure 1 ).
The mechanisms of lipid deposition in tendon
The direct impact of hypercholesterolaemia on tendon is cholesterol deposits within tendon tissues, along with the changes of tendon mechanical properties [7, 15] . Tendon xanthomas are usually accompanied by an increase in tendon size, correlated with the degree of hypercholesterolaemia [26] . The main constituents of tendon xanthomas are lipids and collagen. In tendon xanthomas, Kruth [15] indicated that unesterified cholesterol accumulated predominantly extracellularly in the tendon as human atherosclerotic lesions, while esterified cholesterol and triglyceride accumulated both extracellularly and intracellularly. Lipid analysis of tendon xanthomas indicated that the lipid was composed of 55% free cholesterol, 28% cholesterol esters and 13% phospholipids [27, 28] . Bhattacharyya et al [29] explored the turnover of xanthoma cholesterol in hypercholesterolaemia patients and suggested total exchangeability of cholesterol between plasma and xanthomas. Accordingly, lipids in tendon xanthomas are more likely to be derived from the circulation rather than from local synthesis, secretion or cell death. These findings were supported by the study of Armstrong et al [30] indicating active uptake of LDL by the lesions within xanthomas. Sugiyama et al [31] determined the presence and distribution of lipoproteins by immunohistochemical methods and indicated that oxidatively modified low-density lipoprotein (oxLDL) appeared to have a similar distribution in xanthoma to that of macrophages. Furthermore, the study demonstrated that oxLDL was associated with macrophages and occurred intracellularly. LDL was detected extracellularly, with a distribution that was different from that of oxLDL [31] . It was assumed that LDL derived from plasma was trapped in the tendon matrix and oxidised by macrophages or other cells. The majority of the xanthoma cells were considered to be derived from macrophages after taking up oxLDL.
Inflammation in the pathological process of tendon pathology
The role of inflammation in the development and progression of cardiovascular diseases is well established. Thus, inflammation is suggested to be the main pathological mechanism of tendon pathology in hypercholesterolaemia patients. Artieda et al [32] indicated that macrophages derived from patients with tendon xanthomas were more likely to form foam cells than macrophages from patients without tendon xanthomas. FH patients with tendon xanthomas showed increased serum tryptase, tumour necrosis factor-a, interleukin-8, and interleukin-6 concentrations than FH patients without tendon xanthomas. These authors proposed that tendon xanthomas formation was associated with Figure 1 The pathogenic mechanisms of hypercholesterolaemia on tendon. MMPs Z matrix metalloproteinases; LDL Z low-density lipoprotein; TNF-a Z tumour necrosis factor alpha; IL-8 Z interleukin 8; IL-6 Z interleukin 6.
higher intracellular lipid content and higher inflammatory response of macrophages. In addition, Oosterveer et al [33] indicated that variants in the ALOX5AP (5-lipoxygenase activating protein) gene were associated with the presence of tendon xanthomas in FH patients. ALOX5AP is involved in the biosynthesis of leukotrienes by mediating the activity of 5-lipoxygenase. Leukotrienes promote leucocyte chemotaxis and increase vascular permeability. The authors concluded that inflammation was a pathogenic factor of tendon xanthomas. CXCL3 is a chemokine belonging to the growth-regulated oncogene family, which acts as mediators in allergy, inflammation and immunity. The study by MartinFuentes et al [34] indicated that chemokines belonging to the CXC family could play an important role in the aetiology of tendon xanthomas. CXCL3 was a possible biological marker of onset and development of tendon xanthomas.
Hjuler Nielsen et al [35] concluded that lipoproteinassociated oxidative stress was involved in tendon xanthomas by inducing proinflammatory monocytes and increased release of MMPs. These above studies consistently showed that inflammation was involved in the development of tendon xanthomas.
Tendon structural changes in hypercholesterolaemia environment
Hypercholesterolaemia environment would alter tendon homoeostasis. Hypercholesterolaemia was associated with decreased synthesis of noncollagenous proteins and decreased incorporation of extracellular matrix components [36] . Nakano et al [37] explored the pathogenesis of tendon xanthomas in rabbits and showed that a large number of blood vessels were seen in the xanthomas tissues. Immunohistochemical evaluation revealed that the xanthoma plaques contained endothelial cells and macrophages. Nunes et al [38] investigated the effects of hypercholesterolaemia on the collagen composition of urinary bladder wall and indicated that hypercholesterolaemia induced morphological alterations of collagen fibres and the amounts of type III collagen. Oberkersch et al showed that hypercholesterolaemia affected proteoglycans synthesis [39] . In summary, current evidence suggested that hypercholesterolaemia could alter the tendon microenvironment via local changes in protein synthesis and extracellular matrix remodelling.
Changes in mechanical properties of tendon in hypercholesterolaemia environment
Hypercholesterolaemia could affect the mechanical strength of plaques by inducing local collagen loss and render atherosclerotic plaques prone to rupture [40] . The effects of hypercholesterolaemia on biomechanical properties of tendon have been explored in animal models. Hypercholesterolaemia is believed to contribute to increased tendon injury in several ways. Beason et al [7] explored the effect of high cholesterol on tendon properties in mice and indicated that there was a detrimental effect of hypercholesterolaemia on tendon properties. In addition, another study by Beason et al [8] explored the effect of hypercholesterolaemia on supraspinatus tendon elastic mechanical properties in mice, rats and monkeys. The authors concluded that hypercholesterolaemia could lead to an increase in stiffness and elastic modulus of the supraspinatus tendons in these species. Hypercholesterolaemia-related changes on mechanical properties might lead to the increased rates of tendon injury. Chung et al [41] explored the effect of hyperlipidaemia on fatty infiltration and tendon-to-bone healing in a rabbit model and demonstrated that hyperlipidaemia had a deleterious effect on fatty infiltration and tendon-to-bone healing. Hypercholesterolaemia could alter the biomechanical properties of tendon and thus render tendon prone to injury.
Managements for tendon pathology in hypercholesterolaemia patients
The best approach towards tendon pathology in patients with hypercholesterolaemia is treating the metabolic disorder of lipid metabolism. When lifestyle changes are not effective in lowering the serum cholesterol, statins are recommended for the first-line treatment. Statins are the most widely prescribed medications to treat hyperlipidaemia and reduce the risk of cardiovascular diseases and related mortality [42, 43] . Several studies have demonstrated that statins are effective in decreasing the size of tendon xanthomas [44, 45] . Statins work by lowering serum cholesterol and are therefore associated with mobilisation of cholesterol from tendon xanthomas. In the patients without FH, use of statins is associated with a lower risk of developing tendon pathology when compared with no statin use [10] . However, statins are known to have a potentially deleterious effect on muscle. Use of statins was associated with myalgia, muscle injury, increase in creatine kinase and even rarer rhabdomyolysis [46] . In addition, several studies suggested that use of statins might be associated with tendon pathology and tendon ruptures [47, 48] . Thus, the benefits of statins on tendon pathology needed to be balanced with the potential adverse effects on tendon. The goal of cholesterol reduction in patients with FH is minimal reduction 50% of LDL cholesterol or at ideal LDL cholesterol level [14] . When high-dose statins are not effective in lowering the serum cholesterol, second-line drugs such as ezetimibe, PCSK9 inhibitors, niacin or bile acid sequestrants should be added to further decrease the cholesterol levels [14] . The combination of statins and ezetimibe decreases both the production of cholesterol in the liver and absorption of dietary cholesterol in small intestine [49] . Adding PCSK9 inhibitor should be considered if the ideal goal of cholesterol reduction could not be reached after treatment with high-dose statins plus ezetimibe [50] . Bile acid sequestrants and niacin are optional depending on the availability, toxic effects, and costs. Other approaches including lomitapide, mipomersen, lipoprotein aphaeresis and liver transplantation are not commonly prescribed and could be considered when the above triple-drug therapies (statins, ezetimibe and PCSK9 inhibitor) are not effective [14] . Finally, surgical resection of the tendon xanthomas might be considered in some severe cases [51] .
Besides control of hypercholesterolaemia, several approaches were suggested to promote tendon regeneration after removing primary diseases. Popular injectable substances included growth factors, platelet-rich plasma, autologous blood, mesenchymal stem cells, stromal vascular fraction and bone marrow aspirate concentrate. A metaanalysis of controlled studies has shown that platelet-rich plasma is a safe and promising therapy in the treatment of recalcitrant patellar tendinopathy [52] . Another study indicated that platelet-rich plasma could ameliorate the pain of tendinopathy in the intermediateelong term compared with the control interventions [53] . A recent pilot study revealed that there was a therapeutic value of mesenchymal stem cell injection for treating chronic tendinopathy [54] . Usuelli et al [55] indicated that intratendinous adipose-derived stromal vascular fraction injection provided a safe and efficacious treatment for Achilles tendinopathy. A recent study systematically reviewed the concept and clinical applications of bone marrow aspirate concentrate in tendon pathology [56] . The authors concluded that there were only limited clinical studies available and future randomised controlled studies were highly needed.
Conclusion
Current evidence generally suggested that hypercholesterolaemia was an important risk factor in the development and progression of tendon pathology. The severity of hypercholesterolaemia was correlated with the severity of tendon pathology. Hypercholesterolaemia lead to the structural, inflammatory and mechanical changes in tendons, which predispose hypercholesterolaemia patients to a greater risk of tendon pathology. The strict control of hypercholesterolaemia would mitigate the development and progression of tendon pathology.
